Third Arc Bio provides a platform for creating multifunctional antibodies that can bind multiple disease-relevant antigens and recruit different immune cell types.
Funding
$197.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current antibody therapeutics are limited to single‑target engagement, which often fails to produce sufficient efficacy in complex diseases such as solid tumors and inflammatory disorders. This constraint hampers the ability to orchestrate coordinated immune responses needed for durable clinical outcomes.
Solution
Third Arc Bio develops a platform for multifunctional antibodies that simultaneously bind multiple antigens and recruit distinct immune cell populations. By engineering “immune‑synapse” molecules—such as masked CD3 T‑cell engagers using its SAFEbody® technology—the company creates therapeutics that activate T cells only within the tumor microenvironment, reducing off‑target toxicity. The platform supports rapid generation of bispecific or multispecific formats, enabling preclinical and clinical programs across oncology and immunology & inflammation. Clinical candidates, including ARC101 for CLDN6‑positive cancers, are advancing through early‑stage trials, demonstrating the feasibility of this next‑generation antibody approach.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking advanced antibody platforms to develop next‑generation therapies for solid tumors, hematologic malignancies, and inflammatory diseases.
Features
- Multifunctional antibody formats that engage two or more disease‑relevant targets and multiple immune cell types
- SAFEbody® masked CD3 T‑cell engager technology that activates T cells selectively in target tissues
- Modular platform allowing rapid design and optimization of bispecific and multispecific constructs
- Capability to address solid tumor antigens (e.g., CLDN6) and inflammatory pathways within a single therapeutic molecule
- Preclinical and clinical pipeline spanning oncology and immunology & inflammation indications